GSK reports phase Ib data for Mo-Rez in platinum-resistant ovarian cancer
GSK said mocertatug rezetecan produced a 62% confirmed response rate and 12.2-month median duration of response in the BEHOLD-1 trial, with five phase III studies now underway.
SEC filing